NLM Digital Collections

Search

Start Over Subjects Drug Costs ✖Remove constraint Subjects: Drug Costs Subjects Economics, Pharmaceutical ✖Remove constraint Subjects: Economics, Pharmaceutical Publication Year 2017 to 2019 ✖Remove constraint Publication Year: <span class="from" data-blrl-begin="2017">2017</span> to <span class="to" data-blrl-end="2019">2019</span>

1. The effect of Medicare Part D on evergreening, generic entry, and drug prices

Author(s):
Sanzenbacher, Geoffrey T., author
Wettstein, Gal, author
Publication:
Chestnut Hill, MA : Center for Retirement Research at Boston College, May 2019
Subject(s):
Drug Costs
Drugs, Generic -- economics
Medicare Part D -- economics
Patents as Topic
Aged
Drug Industry -- economics
Economics, Pharmaceutical
Humans
United States
United States. Food and Drug Administration.
Medical Expenditure Panel Survey (U.S.)

2. Medicare Part D

Author(s):
Steiner, David J., author
Publication:
[Toronto, Ontario] : Thomson Reuters, 23-December-2019
Subject(s):
Drug Costs
Medicare Part D -- economics
Medicare Part D -- legislation & jurisprudence
Biosimilar Pharmaceuticals -- economics
Cost Control -- legislation & jurisprudence
Drugs, Generic -- economics
Economics, Pharmaceutical
Financing, Personal
Fraud
Legislation, Drug
Medicare Part C
Opioid-Related Disorders
Humans
United States
United States. Department of Health and Human Services.
Centers for Medicare & Medicaid Services (U.S.)

3. Drug discount program: status of agency efforts to improve 340B program oversight : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate

Publication:
Washington, DC : United States Government Accountability Office, May 15, 2018
Subject(s):
Drug Costs
Economics, Pharmaceutical
Government Regulation
Medicaid -- economics
United States
United States. Health Resources and Services Administration.

5. Drug discount program: improvements needed in federal oversight of compliance at 340B contract pharmacies : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives

Publication:
Washington, DC : United States Government Accountability Office, July 11, 2018
Subject(s):
Drug Costs
Economics, Pharmaceutical
Pharmacies -- economics
Contract Services
Government Regulation
United States
United States. Health Resources and Services Administration.

6. Medicare Part B drug payments: impact of price substitutions based on 2017 average sales prices

Publication:
[Washington, D.C.] : U.S. Department of Health and Human Services, Office of Inspector General, August 2019
Subject(s):
Cost Control
Cost Savings
Drug Costs
Insurance, Health, Reimbursement
Medicare Part B -- economics
Reimbursement Mechanisms
Economics, Pharmaceutical
Humans
United States
Centers for Medicare & Medicaid Services (U.S.)